Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-23
1999-12-07
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31505
Patent
active
059984228
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to compositions containing quinazolinones. More particularly, the present invention relates to a composition for attenuating mesangial cell proliferation, comprising as active ingredient therein a quinazolinone derivative as herein defined.
In U.S. Pat. No. 3,320,124, issued in 1967, there is described and claimed a method for treating coccidiosis with quinazolinone derivatives.
Halofuginone, otherwise known as 7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-quinazo linone, was first described and claimed in said patent by American Cyanamid Company, and was the preferred compound taught by said patent and the one commercialized from among the derivatives described and claimed therein.
Subsequently, U.S. Reissue Patent 26,833 and U.S. Pat. Nos. 4,824,847; 4,855,299; 4,861,758 and 5,215,993 all relate to the coccidiocidal properties of halofuginone, which U.S. Pat. No. 4,340,596 teaches that it can also be used for combatting theileriosis.
In 1991, one of the present inventors published an article reporting that reduced collagen synthesis was noted and identified as an important causitive factor in the skin tearing and reduced skin strength of fowl treated with halofuginone, administered in the amounts recommended for use as a coccidiostat. It was also found that, at the cellular level, halofuginone suppressed collagen synthesis by avian skin fibroblasts [I. Granot, et al., Poult. Sci., Vol. 70, pp. 1559-1563 (1991)].
At that time, however, it was neither taught, recognized or suspected that halofuginone or the related quinazolinone derivatives taught in U.S. Pat. No. 3,320,124 could be effectively used for treatment of fibrotic diseases and for related cosmetic applications, and for good reason.
Clinical conditions and disorders associated with primary or secondary fibrosis, such as systemic sclerosis, graft-versus-host disease (GVHD), pulmonary and hepatic fibrosis and a large variety of autoimmune disorders, are distinguished by excessive production of connective tissue, resulting in destruction of normal tissue architecture and function. These diseases can best be interpreted in terms of perturbations in cellular functions, a major manifestation of which is excessive collagen deposition.
It is generally recognized that at present, most treatments of fibrotic diseases are ineffective and have little effect upon their inexorable pathological progression. Various attempts have been made in order to reduce collagen deposition in the extracellular space. As is known, progressive fibro-proliferative diseases exhibit excessive production of connective tissues, which results in destruction of normal tissue architecture and function. The crucial role of collagen in fibrosis has prompted attempts to develop drugs that inhibit its accumulation [K. I. Kivirikko, Annals of Medicine, Vol. 25, pp. 113-126 (1993)].
Such drugs can act by modulating the synthesis of the procollagen polypeptide chains, or inhibit some specific post-translational events, which will lead either to reduced formation of extra-cellular collagen fibers or to an accumulation of fibers with altered properties. Only a few inhibitors of collagen synthesis are available, despite the importance of this protein in sustaining tissue integrity and its involvement in various disorders.
Cytotoxic drugs have been used in an attempt to slow collagen-producing fibroblast proliferation [J. A. Casas, et al., Ann. Rhem. Dis., Vol. 46, p. 763 (1987)], among them colchicine, which slows collagen secretion into the extracellular matrix [D. Kershenobich, et al., N. Engl. J. Med., Vol. 318, p. 1709 (1988)] and inhibitors of key collagen metabolism enzymes [K. Karvonen, et al., J. Biol. Chem., Vol. 265, p. 8415 (1990) and C. J. Cunliffe, et al., J. Med. Chem., Vol. 35, p. 2652 (1992)].
Unfortunately, none of these inhibitors are collagen-type specific. Also, there are serious concerns about toxic consequences of interfering with biosynthesis of other vital collagenous molecules, such as Clq
REFERENCES:
patent: 4340596 (1982-07-01), Schein
patent: 5449678 (1995-09-01), Pines et al.
Nagler Arnon
Pines Mark
Slavin Shimon
Vlodavsky Israel
Agricultural Research Organization Ministry of Agriculture
Goldberg Jerome D.
Hadasit & Medical Research Services & Development Company, Ltd.
LandOfFree
Quinazolinone-containing pharmaceutical compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolinone-containing pharmaceutical compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolinone-containing pharmaceutical compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-824143